can you play real slots online

Sowei 2025-01-13
The Gunners delivered the statement Champions League victory their manager had demanded to bounce back from a narrow defeat at Inter Milan last time out. Goals from Gabriel Martinelli, Kai Havertz, Gabriel Magalhaes, Bukayo Saka and Leandro Trossard got their continental campaign back on track, lifting them to seventh place with 10 points in the new-look 36-team table. It was Arsenal’s biggest away win in the Champions League since beating Inter by the same scoreline in 2003. “For sure, especially against opposition we played at their home who have not lost a game in 18 months – they have been in top form here – so to play with the level, the determination, the purpose and the fluidity we showed today, I am very pleased,” said Arteta. “The team played with so much courage, because they are so good. When I’m watching them live they are so good! They were all exceptional today. It was a big performance, a big win and we are really happy. “The performance was there a few times when we have played big teams. That’s the level that we have to be able to cope and you have to make it happen, and that creates belief.” A memorable victory also ended Sporting’s unbeaten start to the season, a streak of 17 wins and one draw, the vast majority of which prompted Manchester United to prise away head coach Ruben Amorim. The Gunners took the lead after only seven minutes when Martinelli tucked in Jurrien Timber’s cross, and Saka teed up Havertz for a tap-in to double the advantage. Arsenal added a third on the stroke of half-time, Gabriel charging in to head Declan Rice’s corner into the back of the net. To rub salt in the wound, the Brazilian defender mimicked Viktor Gyokeres’ hands-over-his-face goal celebration. That may have wound Sporting up as they came out after the interval meaning business, and they pulled one back after David Raya tipped Hidemasa Morita’s shot behind, with Goncalo Inacio netting at the near post from the corner. But when Martin Odegaard’s darting run into the area was halted by Ousmane Diomande’s foul, Saka tucked away the penalty. Substitute Trossard added the fifth with eight minutes remaining, heading in the rebound after Mikel Merino’s shot was saved. A miserable night for prolific Sporting striker Gyokeres was summed up when his late shot crashed back off the post.can you play real slots online

After inclement weather canceled all three Birds of Prey World Cup races last December, Ski and Snowboard Club Vail alumnus Kyle Negomir was all smiles after the first day of downhill training Tuesday morning. “It’s sunny, we’re skiing downhill — life’s good,” the U.S. Ski Team athlete said after posting the seventh-best time, and fastest American split on the 753-meter slope. “It was good. I think it took everyone a little bit by surprise — it always does, the first World Cup,” the 26-year-old continued. “I think there was a lot more terrain with how much snow they had this year. They were able to build a lot of fun stuff and it makes it run a little bit differently than normal. I think some of those bumps were more aggressive than some of us were expecting.” Miha Hrobat posted the top time on Tuesday. The 29-year-old Slovenian — who has never been on a World Cup podium but won the 2015 World Junior super-G title — stopped the clock in Red Tail Stadium at 1 minute, 41.21 seconds, 0.61 clear of Swiss star Marco Odermatt. Austrian veteran Vincent Kriechmayr — who won the super-G in Beaver Creek in 2017 and was second in the downhill in 2019 — was 22nd on Tuesday. “Pretty tough this year, but I mean the snow conditions are amazing,” the 18-time World Cup winner said. “Birds of Prey is still one of the most difficult tracks of the whole year. I try my best, but today was a little bit struggling.” Top 10 U.S. finishers (place, name, time) Noticeably absent from the field was Aleksander Aamodt Kilde , who won back-to-back Birds of Prey races in both 2021 and 2022 . The Norwegian obviously didn’t get a chance to three-peat last year and is still recovering from injuries sustained in a downhill crash on the Wengen Lauberhorn on January 13. “We want to see him here; I mean it’s always impressive to see him,” Kriechmayr said. “He steps our sport to the next level. It’s quite impressive to watch him.” Bryce Bennett was the next American after Negomir, coming through in 21st. The two-time Olympian — who won the first World Cup downhill of the 2023-2024 season — echoed Negomir’s sentiment regarding recent snowfall’s effect on course dynamics. “The surface is amazing and with that extra snow they’re able to build some pretty big terrain into the downhill, which generally we don’t get to see just because of a lack of snow this time of year,” Bennett stated. The 14-year U.S. Ski Team veteran said the flow and feel reminded him of the 2015 World Championships held at Beaver Creek. “For me, personally, I like that because I’m a tall guy, so I can deal with it a little bit better than some,” he said. One athlete who wasn’t satisfied with how he navigated the challenges was Ryan Cochran-Siegle. Having finished sixth in 2019 and 2021 and seventh in 2022 at Birds of Prey, the Olympic silver medalist said he arrived Tuesday brimming with confidence. “I was trying to stick to that, but didn’t anticipate a lot of the terrain as well as I should have,” the 32-year-old American said after coming through with the 35th-best time. “I was trying to find speed, trying to ski aggressive in places and I think there was just a lot of places that it was too direct, too over the top. So, I got to figure out a way to tone it back, not get dragged so much in places.” Looking ahead to Friday’s downhill, Kriechmayr said the secret to winning at Beaver Creek is the same as any other World Cup event. “You know, just keep pushing, totally on the limit,” the 2021 world championship super-G and downhill double-gold medalist said. “No mistakes and yeah, that’s what you need to win here. We’ll see who’s the best on Saturday and Sunday.” All told, nine Americans completed Tuesday’s training run. Negomir’s fellow SSCV alumni, River Radamus finished 63rd, 3.68 seconds off the pace. The Edwards native will compete in the super-G and giant slalom on Dec. 7 and 8, respectively, but not the downhill on Dec. 6. Even though Negomir had a good day, he’s still hungry for more. “I was happy with the way I approached things and I think I kept rolling well, but there were some kind of key sections where I feel like I made big mistakes and gave a lot of time away,” he said before adding that ultimately, you can’t put too much stock in a training run anyway. “I mean, I think any day you’re able to be fast, it’s good for your confidence,” he continued. “I’ve been skiing fast in the prep period — but trying to keep in mind that you don’t get paid for training runs. So, hopefully we can use this as a little bit of momentum going into the days that actually count.”NYPD Commissioner Jessica Tisch received strong backing Sunday from her former boss — ex-Commish Ray Kelly– as she dramatically moves to clean up the US’ scandal-ridden largest police department. “I have a lot of confidence in the new police commissioner, Jessica Tisch. She worked directly for me,” Kelly said on 77 WABC radio’s ”The Cats Roundtable” show. ”She’s headed two major city agencies. She’s an excellent manager. She can be a pretty stern taskmaster. I think we’re on the right track,” he told host John Catsimatidis. Tisch ousted dozens of NYPD bosses in a shocking Saturday purge, beginning with the department’s Internal Affairs Bureau, a week after The Post revealed that the agency’s highest ranking uniformed police officer, Jeffrey Maddrey, was allegedly trading overtime for sex at headquarters. Tisch began her career at the NYPD as a counterterrorism analyst in 2008 under Kelly, the longest serving police commissioner in the department’s history. She eventually became the deputy commissioner of information technology and oversaw the NYPD’s 911 operations before running the city Departments of Information Technology and Telecommunications and Sanitation. Kelly, who served as police commissioner under Mayors David Dinkins and Mike Bloomberg, said there are pressing problems in the NYPD that Tisch is grappling with. “We’ve had tough times in the department. We had the overtime scandal . People are leaving in big numbers,” he said. “The department, having 54,000 people, is always going to have some issues, some problems. But I’m positive about what’s going to happen in the next year,’’ he said. Kelly indicated he has less confidence in Mayor Eric Adams, who faces re-election in 2025 while fighting federal corruption charges at a trial scheduled in the spring. Adams maintains his innocence. The Big Apple’s former top cop touted what he called the city’s 20-year law-and-order “renaissance” under ex-Mayor Rudy Giuliani and Bloomberg, adding, “People sort of took that for granted.” Kelly claimed the city’s quality of life and crime started to worsen under former Mayor Bill de Blasio, and “I don’t think Mayor Adams has done anything to change that.” He said the City Council has swung too far to the left, citing the influence of the Democratic Socialists of America. ”We were a little bit asleep at the switch, and this is what we got,” he said. ”The City Council has been a real problem ... for the city and certainly for the police department. They want to tie the hands of the police. They continue to do it. They certainly hurt the quality of life in New York by doing that. These elections are going to be very important,’’ he said. Kelly, who headed the US Customs Service under then-President Bill Clinton, was bullish about President-elect Donald Trump returning to the White House. The former Marine said the nation needed a “course correction” after the border crisis and inflation that occurred during President Biden’s term. “I just can’t believe what happened at the border. There was no explanation why that was going on,” he said. Trump will “send a good signal that there is a new sheriff in town” by ramping up deportations of illegal migrants, particularly criminals,’’ the ex-top cop said. “We need to protect our borders. Otherwise, we won’t have a country,” Kelly said.More than two decades ago, physicists-by-training Colin Hill and Iya Khalil, PhD, co-founded Gene Network Sciences (GNS), a biosimulation company based in Somerville, MA, on the back of the Human Genome Project and the growing excitement around genomics and multiomics. The start-up was an early entrant in the bold new era of systems biology that was being championed by the likes of George Church, PhD, and Lee Hood, MD, PhD. (Khalil moved to big pharma in 2020 and is currently vice president and head of data, AI, and genome sciences at Rahway, NJ-headquartered pharma giant Merck & Co.) Few people were talking about artificial intelligence (AI) back then, but the roots were already being laid, as Hill noted at a virtual summit hosted by on October 30 that drew more than 5,000 registrants. “From the beginning, we were an AI company, but one really focused on human biology, the biological mechanisms of human disease,” he recalled. “The terms that were floating around kept on evolving from bioinformatics to big data to precision medicine to AI.” Two years ago, GNS was rebranded as Aitia. The new name, which is derived from the ancient Greek word for “cause,” refers to the company’s use of causal inference models to uncover the causal mechanisms of diseases. Hill, who today is Aitia’s CEO, noted that the new name was adopted “to indicate our move to being platform therapeutics.” At the virtual summit, Hill participated in a session on The Business of AI in Drug Discovery along with Simon Barnett (a research director at Dimension, a New York, NY-based venture capital firm) and Sabrina Yang, PhD (co-founder and chief innovation officer at Watertown, MA-based Empress Therapeutics). During the session, Hill observed that although most of the buzz around AI in biotechnology is around the need to transform the discovery and design of small molecules and antibodies, bigger problems loom both upstream and downstream. He asked, “What are the right drug targets to go after? Can we start to unravel the actual underlying circuitry of human disease?” Such questions vex us despite all we’ve learned in the two decades that have passed since the Human Genome Project’s completion. “We’re lucky if we know 5% of the genetic and molecular circuitry of disease,” Hill said. “That’s clearly at the heart of why drug discovery and clinical development has been such a trial-and-error process with persistent 80–90% failure rates in clinical development.” From the outset, Hill’s focus has been to apply causal AI (based on the Turing Award–winning work of Judea Pearl, PhD) to reverse engineer the hidden circuitry of disease from human multiomics data and animal models. “We call the resulting models Gemini digital twins, because they are becoming more accurate replicas of human disease, more so than an animal model or cells on plastic will ever be,” Hill continued. These replicas are used to conduct computational experiments, simulating the equivalent of small interfering RNA knockdowns in silico to discover hidden drivers of disease progression, which can become drug targets once validated. Another goal downstream of designing drugs is to improve the design of clinical trials. “It takes a village,” Hill said. “I think together we will be transforming biomedicine in a major way soon.” Simon Barnett joined Dimension as research director from St. Petersburg, FL-based ARK Invest in 2023, believing the $350-million “venture vehicle” was the right fit for his growing interest in the critical importance of computation on life sciences. At the virtual summit, Barnett predicted that over the next 5–10 years, a small tranche of companies wearing the “tech bio” moniker will emerge, and that “every new company in the space, and increasingly in large pharma as well, [will] make computation a central part of what they’re doing rather than something that’s a bolt-on or secondary to the central mission of making medicine.” Barnett also shared his thoughts about the digitalization of the life sciences. For example, he said that it is about “combining high-throughput experimentation and next-generation computational techniques to tackle some of the biggest problems in drug development, diagnostics, and clinical trial design.” Most AI-focused biotech companies are focused on making drugs, but these companies also need to consider factors such as disease indications, modalities, and strategies for reaching the clinic. “These companies are product businesses at the end of the day,” Barnett said. “They need to be aware of the types of risk that investors have a palate for. It’s a very different economic regime now than it was a couple years ago.” Another priority is having either proprietary data or a valuable data-generating platform. These are “essential ingredients for developing a compelling story that would attract investment in this era,” compared to 5–10 years ago, says Barnett. A key for attracting capital is having some level of validation of the technology, especially in the context of pharma collaborations. Hill’s company Aitia recently announced oncology drug discovery partnerships with Espoo, Finland-headquartered Orion Pharmaceuticals and Suresnes, France-headquartered Servier. Such collaborations are important, Hill said, as they provide evidence that respected biotechnology and pharmaceutical companies have vetted the technology and placed their bets with the company. He added that such deals also drive revenue and allows his company “to get to some very interesting places without having to raise hundreds of millions or even billions of dollars.” Having an interdisciplinary team—one that includes not just experts in computational AI, but also experts in other aspects of drug discovery—will also remain a priority for investment considerations. Hill suggested that growth will come as the industry starts to see Phase IIa readouts that are positive, especially if they reflect discoveries that would not have been made but for the data and the AI technology. “When we see the first drug candidate start to have some success against a biological target that truly no-one knew before AI found it—that’s when we’re going to say, ‘Aha, we’ve entered this new era,’” Hill declared. This new AI era is not just about understanding protein folding or molecular design of therapeutics, but about grasping the complexity of human biology. Hill indicated that he anticipates more investment will enter the space even before drugs reach the market. “It will be fantastic when that happens and we get a drug to market,” he said. “But the game is going to be played out and won or lost even before that that endpoint.” Barnett estimates that there are several dozen companies that would self-identify as having machine learning or another data-driven technique as core to their R&D operations. One such company is Salt Lake City, UT-based Recursion Pharmaceuticals, which began with a high-throughput imaging platform to deconvolute novel biology. Last summer, the company announced plans to merge with Oxford, UK-based Exscientia, which is, like Recursion, a high-profile, publicly traded AI company. While companies such as New York, NY-headquartered Schrödinger are using AI to design and optimize better molecules, others are solving for biology first. According to Barnett, companies focused on biology should ask, “How can I use AI to find causally relevant mechanisms and targets from, say, very complex human data, using that to deconvolute the most exciting biological mechanisms to pursue?” Sabrina Yang is a senior principal at Cambridge, MA-based Flagship Pioneering, a venture creation firm. Best known as the firm behind Moderna (also based in Cambridge), Flagship has also founded more than 100 bioplatform companies, including the aforementioned Empress Therapeutics. According to Yang, Empress Therapeutics uses “the power of AI and genetics to find better small-molecule drug starting points that are already invented by nature inside the human body.” The company uses AI to study genetic clues to the biosynthetic pathways of small molecules and elucidate what these molecules may look like, venturing into previously unknown chemical space. “We hope that this approach will lead to a higher chance of success in the clinic,” Yang said. “We’re starting with molecules that are already pharmacologically active. Without AI, we would not be able to efficiently find the genes that encode for the compounds that are disease- and health-relevant.” She emphasized that AI is critical to understanding how these molecules have co-evolved with us and how they can be “co-opted as drugs that may have better safety advantages.” Yang said that Empress Therapeutics generated 15 small-molecule drug candidates in less than two years with a team of just 30 people, delivering time and cost savings of 50% in comparison with traditional approaches. Ultimately, of course, the company’s approach has to be proven in the clinic, beginning with improved chances of success in Phase I safety trials. If you were to ask each of 10 companies for its favorite list of targets, Yang said, you would likely find a big overlap between the different companies’ lists. There is still a big need to identify novel mechanisms that will ultimately translate into increased success in the clinic. A major bottleneck is that AI is not yet positioned to immediately improve the speed and cost of clinical development, but Hill sees that changing in the future. True judgment will be seen when filing Investigational New Drug appilications: Are companies progressing drug candidates in which there is greater confidence and mechanistic understanding in the patient population? Will extensive multiomic validation of a target and the corresponding drug enhance the probability of success? Hill predicted there will be a tipping point when AI impacts clinical development. “Yes, speed and cost [improvements] will happen too, but the real cost is in the cost of clinical development failures—that’s the bottleneck. Until we can change that, we’ll be nibbling at the margins.” When AI companies reach the pivotal Phase IIa stage, there are bound to be failures and, Barnett warns, a backlash. “It’s going to be unfortunate,” Hill remarked. Critics will likely find fault with AI technology and complain that it has been overhyped, which could in turn hurt funding cycles. “We’re going to have to push through because, of course, technology is inexorably improving over time.” Another challenge is in data. “The protein databank that powered AlphaFold took decades of curation and tens of billions of dollars,” Barnett said. “We’re just not going to be able to generate datasets of that scale on the fly.” He asserted that data availability, cleanliness, access, and metadata will be critical for companies, regardless of whether they work with clinical data or preclinical/biochemical data.

PHOTOS: Swansboro pulls away from Southwest in high school boys' basketball

HOUSTON (AP) — An elaborate parody appears to be behind an effort to resurrect Enron, the Houston-based energy company that exemplified the worst in American corporate fraud and greed after it went bankrupt in 2001. If its return is comedic, some who lost everything in Enron’s collapse aren’t laughing. “It’s a pretty sick joke and it disparages the people that did work there. And why would you want to even bring it back up again?” said former Enron employee Diana Peters, who represented workers in the company’s bankruptcy proceedings. Here’s what to know about the history of Enron and the purported effort to bring it back. Once the nation’s seventh-largest company, Enron filed for bankruptcy protection on Dec. 2, 2001, after years of accounting tricks could no longer hide billions of dollars in debt or make failing ventures appear profitable. The energy company’s collapse put more than 5,000 people out of work, wiped out more than $2 billion in employee pensions and rendered $60 billion in Enron stock worthless. Its aftershocks were felt throughout the energy sector. Twenty-four , including , were eventually convicted for their roles in the fraud. Enron founder Ken Lay’s convictions were vacated after he died of heart disease following his 2006 trial. On Monday — the 23rd anniversary of the bankruptcy filing — a company representing itself as Enron announced in a news release that it was relaunching as a “company dedicated to solving the global energy crisis.” It also posted a video on social media, advertised on at least one Houston billboard and a took out a full-page ad in the Houston Chronicle In the minute-long video that was full of generic corporate jargon, the company talks about “growth” and “rebirth.” It ends with the words, “We’re back. Can we talk?” Enron’s new website features a company store, where various items featuring the brand’s tilted “E” logo are for sale, including a $118 hoodie. In an email, company spokesperson Will Chabot said the new Enron was not doing any interviews yet, but that “We’ll have more to share soon.” Signs point to the comeback being a joke. In the “terms of use and conditions of sale” on the company’s website, it says “the information on the website about Enron is First Amendment protected parody, represents performance art, and is for entertainment purposes only.” Documents filed with the U.S. Patent and Trademark Office show that College Company, an Arkansas-based LLC, owns the Enron trademark. The co-founder of College Company is Connor Gaydos, who helped create a joke conspiracy theory that claims all birds are actually surveillance drones for the government. Peters said that since learning about the “relaunch” of Enron, she has spoken with several other former employees and they are also upset by it. She said the apparent stunt was “in poor taste.” “If it’s a joke, it’s rude, extremely rude. And I hope that they realize it and apologize to all of the Enron employees,” Peters said. Peters, who is 74 years old, said she is still working in information technology because “I lost everything in Enron, and so my Social Security doesn’t always take care of things I need done.” “Enron’s downfall taught us critical lessons about corporate ethics, accountability, and the consequences of unchecked ambition. Enron’s legacy was the employees in the trenches. Leave Enron buried,” she said.

President-elect Donald Trump announced Friday he would work to end the "inconvenient" custom of moving clocks forward one hour every spring, which he said was imposing an unnecessary financial burden on the United States. "The Republican Party will use its best efforts to eliminate Daylight Saving Time, which has a small but strong constituency, but shouldn't! Daylight Saving Time (DST) is inconvenient, and very costly to our Nation," Trump posted on his website, Truth Social. DST was adopted by the federal government during World War I but was unpopular with farmers rushing to get produce to morning markets, and was quickly abolished. Many states experimented with their own versions but it wasn't reintroduced nationwide until 1967. The Democratic-controlled US Senate advanced a bill in 2022 that, like Trump's plan, would bring an end to the twice-yearly changing of clocks, in favor of a "new, permanent standard time." But The Sunshine Protection Act called for the opposite switch -- moving permanently to DST rather than eliminating it -- to usher in brighter evenings, and fewer journeys home in the dark for school children and office workers. The bill never made it to President Joe Biden's desk, as it was not taken up in the Republican-led House. It had been introduced in 2021 by a Republican, Florida Senator Marco Rubio, who is about to join the incoming Trump administration as secretary of state. He said studies had shown a permanent DST could benefit the economy. Either way, changing to one permanent time would put an end to Americans pushing their clocks forward in the spring, then setting them back an hour in the fall. Colloquially the practice is referred to as "springing" forward and "falling" back. The clamor has increased in recent years to make DST permanent especially among politicians and lobbyists from the Northeast, where frigid conditions are normal in the early winter mornings. "It's really straightforward. Cutting back on the sun during the fall and winter is a drain on the American people and does little to nothing to help them," Rubio said in a statement ahead of the vote. "It's time we retire this tired tradition." Rubio said the United States sees an increase in heart attacks and road accidents in the week that follows the changing of the clocks. Any changes would be unlikely to affect Hawaii and most of Arizona, the Navajo Nation, American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the US Virgin Islands, which do not spring forward in summer. ft/nroBy JUAN A. LOZANO, Associated Press HOUSTON (AP) — An elaborate parody appears to be behind an effort to resurrect Enron, the Houston-based energy company that exemplified the worst in American corporate fraud and greed after it went bankrupt in 2001. If its return is comedic, some former employees who lost everything in Enron’s collapse aren’t laughing. “It’s a pretty sick joke and it disparages the people that did work there. And why would you want to even bring it back up again?” said former Enron employee Diana Peters, who represented workers in the company’s bankruptcy proceedings. Here’s what to know about the history of Enron and the purported effort to bring it back. Once the nation’s seventh-largest company, Enron filed for bankruptcy protection on Dec. 2, 2001, after years of accounting tricks could no longer hide billions of dollars in debt or make failing ventures appear profitable. The energy company’s collapse put more than 5,000 people out of work, wiped out more than $2 billion in employee pensions and rendered $60 billion in Enron stock worthless. Its aftershocks were felt throughout the energy sector. Twenty-four Enron executives , including former CEO Jeffrey Skilling , were eventually convicted for their roles in the fraud. Enron founder Ken Lay’s convictions were vacated after he died of heart disease following his 2006 trial. On Monday — the 23rd anniversary of the bankruptcy filing — a company representing itself as Enron announced in a news release that it was relaunching as a “company dedicated to solving the global energy crisis.” It also posted a video on social media, advertised on at least one Houston billboard and a took out a full-page ad in the Houston Chronicle In the minute-long video that was full of generic corporate jargon, the company talks about “growth” and “rebirth.” It ends with the words, “We’re back. Can we talk?” Related Articles Enron’s new website features a company store, where various items featuring the brand’s tilted “E” logo are for sale, including a $118 hoodie. In an email, company spokesperson Will Chabot said the new Enron was not doing any interviews yet, but that “We’ll have more to share soon.” Signs point to the comeback being a joke. In the “terms of use and conditions of sale” on the company’s website, it says “the information on the website about Enron is First Amendment protected parody, represents performance art, and is for entertainment purposes only.” Documents filed with the U.S. Patent and Trademark Office show that College Company, an Arkansas-based LLC, owns the Enron trademark. The co-founder of College Company is Connor Gaydos, who helped create a joke conspiracy theory that claims all birds are actually surveillance drones for the government. Peters said that since learning about the “relaunch” of Enron, she has spoken with several other former employees and they are also upset by it. She said the apparent stunt was “in poor taste.” “If it’s a joke, it’s rude, extremely rude. And I hope that they realize it and apologize to all of the Enron employees,” Peters said. Peters, who is 74 years old, said she is still working in information technology because “I lost everything in Enron, and so my Social Security doesn’t always take care of things I need done.” “Enron’s downfall taught us critical lessons about corporate ethics, accountability, and the consequences of unchecked ambition. Enron’s legacy was the employees in the trenches. Leave Enron buried,” she said. Follow Juan A. Lozano on X at https://x.com/juanlozano70AI has been a boon for marketing, but the dark side of using algorithms to sell products and brands is little studied

Yankees get closer Devin Williams from Brewers for Nestor Cortes, Caleb Durbin

None

WEST READING, Pa.--(BUSINESS WIRE)--Dec 3, 2024-- Customers Bank, the over $21 billion asset subsidiary of Customers Bancorp (NYSE:CUBI), has been named to the Inc . 2024 Best in Business list in the Financial Services category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. The Bank’s industry-leading franchise growth over the last 18 months, in both deposits and market expansion, unique operating model and commitment to principles of sound risk management ensured it stood out among its peers. “We are honored to be named to Inc.’s Best in Business list. Founded by entrepreneurs for entrepreneurs, Customers Bank delivers the product suite of larger financial institutions with a level of service beyond what large banks can offer,” said Sam Sidhu, president and CEO of Customers Bank. “With ‘customer’ in our name and at the very heart of why we exist, we adhere to a unique operating model that is anchored around a single point of contact, a focused product offering and a culture of exceptional customer service.” Inc.’s Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins, like customer expansion, key product launches, increased market share, and industry-defining accomplishments. Companies from a wide range of industries – such as technology, health care, finance, and retail – have been recognized for their success and their positive influence on the business world. The full list can be found on Inc. com and in the upcoming winter print edition of Inc. magazine. “For over 40 years Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman. Inc.’s Best in Business Awards are open to companies of all sizes and types, in all industries and locations. Public, private, nonprofit, subsidiary, U.S.-based, and international companies are all encouraged to apply. Inc. editors and reporters hand-review every application and select Best in Business honorees that, in each of the award categories, have had an outstanding influence on their communities, their industries, the environment, or society as a whole. For more information or to see the complete list, please visit inc.com/best-in-business . About Customers Bank Customers Bancorp, Inc. (NYSE:CUBI) is one of the nation’s top-performing banking companies with over $21 billion in assets, making it one of the 80 largest bank holding companies in the U.S. Customers Bank’s commercial and consumer clients benefit from a full suite of technology-enabled tailored product experiences delivered by best-in-class customer service distinguished by a Single Point of Contact approach. In addition to traditional lines such as C&I lending, commercial real estate lending and multifamily lending, Customers Bank also provides a number of national corporate banking services to specialized lending clients. Major accolades include: No. 1 on American Banker 2024 list of top-performing banks with $10B to $50B in assets No. 29 out of the 100 largest publicly traded banks in 2024 Forbes Best Banks list No. 52 on Investor’s Business Daily 100 Best Stocks for 2023 A member of the Federal Reserve System with deposits insured by the Federal Deposit Insurance Corporation, Customers Bank is an equal opportunity lender. Learn more: www.customersbank.com . About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.'s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, digital, print, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241203333765/en/ CONTACT: Jordan Baucum VP, Corporate Communications jbaucum@customersbank.com KEYWORD: PENNSYLVANIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BANKING PROFESSIONAL SERVICES FINANCE SOURCE: Customers Bancorp, Inc. Copyright Business Wire 2024. PUB: 12/03/2024 04:30 PM/DISC: 12/03/2024 04:30 PM http://www.businesswire.com/news/home/20241203333765/en

0 Comments: 0 Reading: 349